Integrated CMC Development
Integrated Chemistry, Manufacturing and Controls (CMC) development is essential for translating a promising drug candidate into a well-characterized, reproducible, and regulatory-ready pharmaceutical product. Protheragen provides integrated CMC development services that connect API process R&D, preformulation studies, analytical development, quality research, stability studies, and impurity investigations within a coordinated development framework. Our CMC capabilities support pharmaceutical development from early-stage research through clinical development and commercial preparation. By integrating process and analytical development, we help establish appropriate control strategies, identify development risks at an early stage, and generate scientifically sound data to support regulatory submissions.
Overview of Integrated CMC Development
CMC development involves multiple interconnected activities, including drug substance process development, physicochemical characterization, analytical method development, impurity profiling, stability evaluation, and quality research.
A change in one area can directly affect another. For example, process conditions may influence impurity profiles, solid-state properties may affect formulation and analytical testing, while analytical methods must be sufficiently specific and sensitive to support process development and product quality assessment.
Fig.1 Current CMC Data Management and Content Authoring Process. (Ahluwalia, K., et al., 2022)
Our Services
Protheragen integrates drug substance process development, preformulation studies, and analytical and quality research to support key CMC activities throughout drug development. These complementary services provide a coordinated approach to process understanding, product characterization, quality assessment, and risk management, helping clients make informed development decisions and advance candidates efficiently toward clinical and commercial stages.
API Process R&D
Protheragen provides API process R&D services covering synthetic route evaluation, process development, process optimization, impurity control, and scale-up support. Our scientists work to improve reaction efficiency, process robustness, product quality, and manufacturing consistency while addressing critical process and material considerations. From early-stage route development to preparation for larger-scale manufacturing, our API process development capabilities help establish practical and scalable drug substance processes that support subsequent analytical, quality, clinical, and commercial development.
Preformulation Study Services
Preformulation studies provide essential information about the physicochemical and solid-state properties of a drug substance before formulation and process development are finalized. Protheragen offers preformulation research covering solubility, pKa, solid-state properties, polymorphism, salt screening, thermal behavior, hygroscopicity, and API–excipient compatibility. These studies help identify formulation and manufacturing risks at an early stage and generate scientific data to support formulation selection, analytical development, stability assessment, and overall CMC strategy.
Analytical Development and Quality Research
Protheragen provides integrated analytical development and quality research services to characterize drug substances and products, establish appropriate analytical methods, investigate impurities, and evaluate stability. Services include analytical method development and validation, release testing, stability studies, forced degradation research, impurity characterization, and related quality assessments. By connecting analytical development with process and product development, our team helps establish reliable quality control strategies and generate the data required to support pharmaceutical development and regulatory CMC activities.
Integrated CMC Workflow
The effectiveness of CMC development depends on close coordination between process development, material characterization, analytical development, stability research, and impurity control.
Our integrated workflow can be structured as:
1. Development Strategy
Define development objectives, product requirements, critical quality considerations, and analytical needs.
2. API Process Development
Evaluate synthetic routes and develop a robust, scalable process.
3. Preformulation & Characterization
Characterize physicochemical and solid-state properties and identify potential development risks.
4. Analytical Method Development
Develop fit-for-purpose methods for identity, assay, impurities, physical properties, and other relevant quality attributes.
5. Impurity & Degradation Investigation
Identify process-related and degradation-related impurities and establish appropriate analytical approaches.
6. Stability Research
Evaluate stability under long-term, accelerated, photostability, and forced degradation conditions as appropriate.
7. Quality Control Strategy
Integrate process understanding, analytical results, impurity profiles, specifications, and stability data.
8. Regulatory CMC Support
Organize development data and analytical/quality information to support regulatory documentation and submission activities.
Key CMC Development Areas
Analytical requirements change as pharmaceutical product progresses from early development to commercialization. Analytical strategies can therefore be adjusted according to the development stage, product characteristics, process changes, and quality objectives.
| CMC Area |
Key Activities |
Development Objectives |
| API Process R&D |
Route design, process development, process optimization, impurity control, process safety evaluation |
Establish a robust and scalable API manufacturing process |
| Preformulation Study Services |
Physicochemical characterization, solid-state studies, polymorph and salt screening, excipient compatibility |
Understand material properties and support formulation development |
| Analytical Development |
Analytical method development, optimization, validation, specification testing and release testing |
Establish reliable analytical methods for quality assessment |
| Stability Research |
Accelerated, long-term, photostability and forced degradation studies |
Evaluate product stability and identify degradation pathways |
| Impurity Related Services |
Impurity isolation, structural characterization, impurity synthesis, genotoxic impurity assessment |
Identify, characterize and control process- and degradation-related impurities |
CMC Support for Different Drug Development Programs
CMC requirements vary according to molecular type, dosage form, development stage, and regulatory strategy. Our integrated CMC capabilities can be adapted to different pharmaceutical development programs.
Small-Molecule Drugs
- API process development
- Route optimization
- Impurity research
- Solid-state characterization
- Analytical method development
- Stability studies
- Release testing
Generic Drug Development
- API and formulation-related CMC studies
- Analytical method development
- Impurity characterization
- Comparative quality research
- Stability studies
- Support for regulatory and quality documentation
Innovative Drug Development
- Early-stage API development
- Preformulation characterization
- Process optimization
- Analytical development
- Stability and degradation studies
- CMC data generation for IND-stage development
Complex and Specialized Products
For projects involving challenging APIs, highly active compounds, complex impurity profiles, or specialized analytical requirements, CMC activities can be structured according to the specific development and quality risks of the product.
Why Choose Protheragen
- Cross-Functional CMC Expertise
Our CMC development approach connects process chemistry, analytical development, physicochemical characterization, impurity research, and stability evaluation to reduce gaps between individual development activities.
- Development-Stage Flexibility
Services can be initiated during early development and expanded as programs progress toward clinical development and commercialization.
Analytical and process data are used to identify development risks, understand material and process behavior, and support scientifically justified development decisions.
- Integrated Project Coordination
A coordinated project structure helps maintain communication between different technical workstreams and supports consistent project execution.
- Regulatory-Oriented Development
CMC activities can be planned with consideration of the data and documentation requirements associated with pharmaceutical development and regulatory submissions.
Protheragen integrates API process R&D, preformulation studies, analytical development, stability research, and impurity-related services within a coordinated CMC development framework. By connecting process, analytical, and quality research from early development through clinical and commercial stages, we help pharmaceutical companies build robust development strategies, identify potential risks earlier, and generate reliable CMC data for subsequent development and regulatory activities. Whether you are developing an innovative drug, generic pharmaceutical product, or a complex drug substance, our integrated CMC capabilities can be tailored to your molecule, development stage, and project objectives. Contact us to discuss your CMC development requirements and identify the appropriate combination of process, analytical, and quality research services for your program.
Reference
- Ahluwalia, K., et al. "The Future of CMC Regulatory Submissions: Streamlining Activities Using Structured Content and Data Management." In Journal of Pharmaceutical Sciences. 2022; 111(5): 1232-1244.
